Ketamine & Glutamate After Brain Injury : a Microdialysis Study

Status Not yet recruiting

Clinical Trial Summary

The objective of the study is to compare the effects of 48 hours ketamine infusion versus sufentanil infusion on brain glutamate concentrations measured with microdialysis after traumatic brain injury.

We hypothesize that ketamine infusion will decrease high glutamate values faster than sufentanil.

Clinical Trial Description

Inclusion of 20 consecutive head trauma patients. Randomization and double-blind to compare the effects of ketamine versus sufentanil on brain glutamate concentrations measured with microdialysis.

Ketamine is an anti-N-methyl-D-aspartate (NMDA) medication. It is supposed to limit excitotoxicity of amino-acids, especially glutamate. Glutamate is known to be elevated in more than 60% of the severe head trauma patients. It induces cortical spreading depression which can aggravate prognosis. It's a daily used medication in anesthesia and intensive care units for sedation and induction of anesthesia. It's the recommended medication for induction of unstable wounded soldiers on the field because of its neutrality on haemodynamic state.

Sufentanil is the reference opioid for sedation in ICU in Europe. It can induce hypotension which is deleterious for cerebral perfusion pressure after brain trauma.

In our unit, patients with severe head injury are monitored by a triple lumen access device including ICP (IntraCerebral Pressure), PtiO2 (oxygen pressure in the brain) and microdialysis. This last monitoring allows measurement of brain parenchymal concentrations of small molecules : glucose, lactate, pyruvate, glutamate, glycerol,.... It's a tool to evaluate the metabolic state of the brain divided into 4 categories : normal, hyperglycolysis, ischemia and metabolic crisis.

Then, we will detail the effects of ketamine on metabolic state of the brain, especially glutamate concentration. Normal values are below 10 micromol/ml. After head trauma it can dramatically increase to values up to 50 or even 100 micromol/ml, with normalization after 24 hours. Ketamine is expected to decrease these high values faster than described in observational studies. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02232347
Study type	Interventional
Source	Direction Centrale du Service de Santé des Armées
Contact	Ambroise MONTCRIOL, MD
Phone	0483162358
Email	ambroise.montcriol@free.fr
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2014
Completion date	May 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03291964` - Rapid MRI for Acute Pediatric Head Trauma
Completed	`NCT02828306` - Computer Based Algorithm for Patient Specific Implants for Cranioplasty in Patients With Skull Defects
Completed	`NCT04505293` - Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas	N/A
Completed	`NCT01448473` - Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients	N/A
Terminated	`NCT00847977` - Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis	Phase 3
Completed	`NCT00622778` - Immunemodulation in Patients With Minor Head Injury	N/A
Completed	`NCT04495634` - Evaluation of a Carbon Nanotube Enabled Solid-State Head CT	N/A
Terminated	`NCT03680911` - NAC for Head Trauma-induced Anosmia	Phase 3
Recruiting	`NCT06173427` - Monitoring of Intracranial Hemorrhage in Non-severe Head Trauma Patients Hospitalized in the UHCD
Completed	`NCT03742427` - Effect of Cervical Collar on the Optic Nerve Sheath Diameter in Minor Head Trauma	N/A
Terminated	`NCT06246500` - Severe Head Trauma: Coagulation and CT-Scan Aggravation.
Withdrawn	`NCT03453749` - Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury	Phase 2
Completed	`NCT00995683` - Preventive Sodium Lactate and Traumatic Brain Injury	Phase 2/Phase 3
Not yet recruiting	`NCT05195606` - The Effect of Auditory and Tactile Stimuli in Traumatic Coma	N/A
Completed	`NCT04020874` - Reducing Head Impact Exposure in Hawaii High School Football	N/A
Not yet recruiting	`NCT06113939` - Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning	N/A
Recruiting	`NCT05386966` - Medicolegal Aspects of Head Trauma
Not yet recruiting	`NCT03704272` - Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral	N/A
Active, not recruiting	`NCT00196131` - Problems With Morphine Use in Patients With a Severe Brain Injury	Phase 1/Phase 2
Withdrawn	`NCT02798601` - Early Induced Hypernatremia for the Prevention and Management of Brain Edema	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ketamine and Glutamate After Brain Injury : a Microdialysis Study — KETABRAIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms